BioCryst Pharma (BCRX) Climbs 12.5% Following Successful Proof of Concept for Oral Factor D Inhibitor, BCX9930
Tweet Send to a Friend
BioCryst Pharma (NASDAQ: BCRX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
